Weekly Funding Opportunities

[med-Research]

NIH Notice NOT-OD-21-180 Clarification and Guidance for Applicants Preparing Applications for the Fall 2021 Due Dates During the COVID-19 Pandemic<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-180.html>

Cigna: Health and Well-being Grants<https://www.cigna.com/about-us/corporate-responsibility/cigna-foundation/health-and-well-being-grants>
The Cigna Foundation is committed to eliminating health disparities and improving health and well-being for all. For this grant cycle, we’re looking to partner with nonprofits who are addressing the root causes of health inequity, including supporting under-resourced and systemically disadvantaged communities with poor social determinants of health.
Programs should focus on chronic disease treatment and prevention, mental and/or behavioral health conditions, dental health, wellness programs, and maternal, prenatal, and newborn health.
$50,000-$100,000 per year for projects of up to 3 years in length.
Due September 24, 2021. Med-RA deadline to receive draft documents: September 13.

Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-22-029.html>
The purpose of this funding opportunity is to support projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.
Due October 5, 2021. Med-RA deadline to receive draft documents: September 22.

Basic Research in Cancer Health Disparities (R03 / R21 / R01 Clinical Trial Not Allowed)
R03<https://grants.nih.gov/grants/guide/pa-files/PAR-21-324.html>
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These small research grants (R03) will support projects on cancer health disparities that can be carried out in a short period of time with limited resources. The projects should propose innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-21-323.html>
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.
Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-21-322.html>
This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3 / UH3 Clinical Trial Required)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-317.html>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and cost-effectiveness research (Stages IV/V).
Due October 6, 2021; February 8, 2022; June 7, 2022; October 4, 2022; February 7, 2023; June 6, 2023; October 3, 2023; and February 6, 2024. Med-RA deadline to receive draft documents for October 6, 2021 due date: September 23.

American Cancer Society: Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services<https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/rfa-role-healthcare-insurance-cancer.html>
A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients. We are keenly interested in supporting rapid learning research to study the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to:

  *   Facilitators and barriers to care
  *   Unintended consequences
  *   Differential experiences and outcomes of patients seeking or receiving care
  *   Best practice models for quality care
  *   Economic Impact
Awards will not exceed $200,000 per year (direct costs) for up to five years.
Due October 15, 2021. Med-RA deadline to receive draft documents: October 4.

Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-313.html>
The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than $125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.

Blueprint MedTech Translator (UG3 / UH3 – Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-315.html>
The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems.
Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.
Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring.
Due October 20, 2021; February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024; June 20, 2024. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/rfa-es-19-011.html>
This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.
Due November 1, 2021; December 1, 2021; January 3, 2022; February 1, 2022; March 1, 2022; April 1, 2022; May 2, 2022; June 1, 2022; July 1, 2022; August 1, 2022; September 1, 2022; and October 3, 2022. Med-RA deadline to receive draft documents for November 1, 2021 due date: October 19.

Selectively Target Technology Development to Understand How Changes or Dysfunction at the Capillary, Arterioles, and Small Lymphatic Vessels Level Can Have Long-term Impact on AD/ADRD (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-22-026.html>
The purpose of this Funding Opportunity Announcement (FOA) is to solicit studies that will advance the mechanistic understanding of small vessel vascular contributions to cognitive impairment and dementia (VCID) through the development of new technologies and innovative methods that enable the imaging and/or functional assessment of the small blood and lymphatic vessels and perivascular spaces of the brain. This program aims to facilitate the development of tools and technology to image, profile and/or mechanistically characterize CNS small blood and lymphatic vessels in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementia (AD/ADRD) animal models or patient populations. The overall goal is to use such technologies or methods to elucidate the mechanisms that link CNS small blood and lymphatic vessel dysfunction to dementia outcomes in the AD/ADRDs, their potential role in repair processes, and their response to therapies. Preclinical studies of small vessel VCID in vitro and/or animal models and pilot human subject studies (that do not meet the NIH definition of clinical trial) are appropriate for this FOA.
Due November 8, 2021. Med-RA deadline to receive draft documents: October 26.

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-057.html>
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) solicits applications for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT), a program that will implement and evaluate multilevel and culturally tailored outreach and education interventions with the primary goal of increasing referral and ultimately, accrual of underrepresented racial/ethnic (R/E) minority populations, to NCI-supported clinical trials (CTs) (National Clinical Trial Network (NCTN<https://www.cancer.gov/research/infrastructure/clinical-trials/nctn>), NCI’s Community Oncology Research Program (NCORP<https://www.cancer.gov/research/infrastructure/clinical-trials/ncorp>), and Experimental Therapeutics Clinical Trials Network (ETCTN<https://ctep.cancer.gov/initiativesPrograms/etctn.htm>)). The target population(s) should include individuals from underrepresented racial/ethnic (R/E) minority populations. Applicants should address cancer health disparities (CHD) through a network of local multidisciplinary and integrated partners that include community health educators (CHEs), lay health advisors (LHAs), community members, healthcare providers, and researchers working in coordination to educate and refer R/E minority populations to NCI-supported CTs, and increase awareness in providers about R/E minority participation in NCI clinical trials. This will require multilevel outreach and education interventions at the CT site, provider, and/or patient levels. The proposed interventions should be informed by relevant theories, frameworks, or models. Further, the interventions should be guided by baseline information on participant, health care provider and facilitator -related strategies for increasing CT referral of R/E minority populations. It is expected that U01 grantees will establish partnerships with the community, primary care providers, and other stakeholders to enhance identification of R/E minority referral barriers and interventions to NCI-supported CTs. The research activities will address key issues that affect diversity in clinical trials and will improve the dissemination of information and care into underserved communities, where they are needed most.
Due November 19, 2021. Med-RA deadline to receive draft documents: November 8.

NSF: Reproducible Cells and Organoids via Directed-Differentiation Encoding (RECODE)<https://www.nsf.gov/pubs/2021/nsf21608/nsf21608.htm?WT.mc_ev=click&WT.mc_id=USNSF_25&utm_medium=email&utm_source=govdelivery>
The National Science Foundation (NSF) Divisions of Chemical, Bioengineering, Environmental and Transport Systems (CBET), Integrative and Organismal Systems (IOS), Molecular and Cellular Biosciences (MCB), and Civil, Mechanical, and Manufacturing Innovation (CMMI) seek proposals that elucidate mechanisms of, and develop strategies to, direct the differentiation of undifferentiated cells into mature, functional cells or organoids. Projects responsive to this solicitation must aim to establish a robustly validated and reproducible set of differentiation design rules, mechanistic models, real-time sensing, control, and quality assurance methods, and integrate them into a workable differentiation strategy. They must also deepen our fundamental understanding of how cells develop and differentiate, to provide insights into mechanisms, molecular machinery, dynamics, and the interplay between cells and their environment, such as cell-cell/cell-microbe and cell-extracellular matrix (ECM) interactions and use this understanding to manipulate cells purposefully. Investigators can choose any undifferentiated cell type from any animal species, including human cell types, as a starting point and choose any appropriate functional product (cell, organoid, etc.) with real-world relevance. The use of non-model systems (e.g., non-human or non-murine systems) is encouraged as is the exploration of non-medical targets. Functional products can span a diverse range of systems (cardiovascular, nervous, immune, etc.). The RECODE program aligns with NSF’s commitment to the development of capabilities in biotechnology that advance the U.S. Bioeconomy. Collaborative proposals, of a duration up to 4 years, with budgets up to $1,500,000 total will be considered. The solicitation will support teams of three or more PI/co-PIs and senior personnel with complementary expertise. Proposals with only one PI or one PI with one other senior personnel are not permitted and will be returned without review. Reflecting the need for thoughtful collaboration and planning required for these projects, Preliminary Proposals are required to be submitted prior to submission of a full proposal.
Preliminary proposal due November 22, 2021. Med-RA deadline to receive draft documents: November 8.

NSF: Ecology and Evolution of Infectious Diseases<https://www.nsf.gov/pubs/2021/nsf21609/nsf21609.htm?WT.mc_ev=click&WT.mc_id=USNSF_25&utm_medium=email&utm_source=govdelivery>
The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, organismal, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease (re)emergence and transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of (re)emergence and transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of vectors and reservoir species or hosts; how the physiology or behavior of the pathogen, vector, or host species biology affects transmission dynamics; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission and disease. Research may be on zoonotic, environmentally-borne, vector-borne, enteric, or respiratory pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to Low- or Middle-Income Countries (LMICs) are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, behaviorists, epidemiologists, evolutionary biologists, entomologists, immunologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases. Maximum award size: $3M (including direct costs).
Due November 24, 2021 and November 16, 2022. Med-RA deadline to receive draft documents for November 24, 2021 due date: November 9.

Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R21 / R01)
Deciphering Immune-CNS interactions in HIV utilizing in-vitro and in-vivo model systems (R21 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-251.html>
The purpose of this Funding Opportunity Announcement is to support studies to comprehend the mechanisms contributing to the CNS comorbidities in people living with HIV on anti-retroviral therapy by deciphering the immune-CNS interactions utilizing novel in-vitro and in-vivo model systems. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Deciphering Immune-CNS interactions in people living with HIV on Anti-Retroviral therapy (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-250.html>
The purpose of these Funding Opportunity Announcement is to support studies to better comprehend the mechanisms contributing to the CNS comorbidities in people living with HIV on anti-retroviral therapy by deciphering the immune-CNS interactions. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Due December 7, 2021. Med-RA deadline to receive draft documents: November 22 (due to Thanksgiving holiday).

HIV Prevention and Alcohol (R34 / R01 Clinical Trials Optional)
R34<https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-017.html>
The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This R34 Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement RFA- AA-21-016<https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-016.html> HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-016.html>
The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This research activity includes the development and testing of new interventions and expansion of existing effective interventions as well as the implementation of these integrative preventive activities in diverse settings and populations. Six areas of research are of primary interest related to alcohol use and related mental health and substance use comorbidities. These include but are not limited to 1) PrEP Utilization, 2) Treatment as Prevention (TasP), 3) Integration of Preventive Intervention Strategies, 4) Prevention-related Cross-cutting Research, 5) Syndemic Approaches and, 6) Implementation and Operations Research.
Due December 16, 2021. Med-RA deadline to receive draft documents: December 6.

Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations in Geographic Hot Spots in the United States (R01 – Clinical Trial Required)<https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-22-001.html>
This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.
Due January 14, 2022. Med-RA deadline to receive draft documents: January 3.

Pharmacokinetics (PK) and Pharmacodynamics (PD) of THC in Cannabis and Cannabis Products (R21 / R01 – Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-039.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-028.html>
The purpose of these Funding Opportunity Announcements is to support human and animal research on the pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) that is present in cannabis and cannabis products.
Due February 9, 2022. Med-RA deadline to receive draft documents: January 27.

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-040.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs. Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities.
Due February 15, 2022; August 15, 2022; February 15, 2023; August 15, 2023; and February 15, 2024. Med-RA deadline to receive draft documents for February 15, 2022 due date: February 2.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210908/c87ffae7/attachment.html>